托法替布治疗重度斑秃及变异型:90例患者研究
该回顾性研究纳入90例≥18岁、头皮脱发≥40%的斑秃患者,评估托法替布的安全性和有效性。主要终点为治疗期间SALT评分百分比变化。在65例潜在应答者中,77%达到临床应答,58%在4至18个月治疗中SALT评分改善>50%。托法替布耐受良好,无严重不良事件。
要点
- 托法替布治疗重度斑秃的潜在应答者中77%达到临床应答。
- 58%的患者在4至18个月治疗中SALT评分改善超过50%。
- 斑秃患者SALT评分改善百分比高于全秃或普秃患者。
核心结论
- 托法替布可考虑用于治疗重度斑秃、全秃和普秃。
- 托法替布的剂量效应需通过随机对照试验进一步明确。
研究设计与样本
- 回顾性研究,纳入90例年龄18岁及以上、头皮脱发至少40%的斑秃患者,接受托法替布治疗。
- 主要终点为治疗期间SALT评分的百分比变化。
主要发现
- 在65例潜在应答者中,77%达到临床应答,58%在4至18个月治疗中SALT评分改善超过50%。
- 斑秃患者SALT评分百分比变化为81.9%,全秃或普秃患者为59.0%。
- 托法替布耐受良好,无严重不良事件。
关键数值与推荐
- 潜在应答者定义为全秃或普秃且当前发作病程10年或以下,或斑秃患者。
- 临床应答定义为SALT评分改善,58%的患者SALT评分改善超过50%。
临床怎么用
- 托法替布可考虑用于重度斑秃、全秃和普秃的治疗。
- 治疗期间需监测SALT评分变化以评估疗效。
局限性
- 数据的回顾性性质。
- 患者数量相对较少。
- 缺乏对照组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Alopecia areata (AA) is a common autoimmune disorder. There are no reliably effective therapies for AA. OBJECTIVE: We sought to evaluate the safety and efficacy of the Janus kinase 1/3 inhibitor, tofacitinib, in a series of patients over an extended period of time. METHODS: This is a retrospective study of patients age 18 years or older with AA with at least 40% scalp hair loss treated with tofacitinib. The primary end point was the percent change in Severity of Alopecia Tool (SALT) score during treatment. RESULTS: Ninety patients met inclusion criteria. Of 65 potential responders to therapy, defined as those with alopecia totalis or alopecia universalis with duration of current episode of disease of 10 years or less or alopecia areata, 77% achieved a clinical response, with 58% of patients achieving greater than 50% change in SALT score over 4 to 18 months of treatment. Patients with AA experienced a higher percent change in SALT score than did patients with alopecia totalis or alopecia universalis (81.9% vs 59.0%). Tofacitinib was well tolerated, and there were no serious adverse events. LIMITATIONS: The retrospective nature of the data, the relatively small number of patients, and lack of a control group are limitations. CONCLUSION: Tofacitinib should be considered for the treatment of severe AA, alopecia totalis, and alopecia universalis; tofacitinib dose response will be better defined by randomized controlled trials.
引用
- Liu LY, Craiglow BG, Dai F, et al. Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients. J Am Acad Dermatol. 2016. PMID: 27816293. doi:10.1016/j.jaad.2016.09.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。